Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency profile exhibits a period of relative stability followed by a significant deterioration in the final quarter. Between March 2022 and March 2026, the organization maintained a controlled leverage structure, characterized by a gradual reduction in financial risk, before experiencing a sharp reversal in June 2026.
- Debt-to-Equity and Debt-to-Capital Ratios
- The debt-to-equity ratio remained largely consistent between 1.09 and 1.44 for several years, reaching a period low of 0.94 by March 31, 2026. This suggests a systematic deleveraging or an increase in equity. However, this trend reversed abruptly in June 30, 2026, with the ratio spiking to 2.22. Similarly, the debt-to-capital ratio remained stable near 0.54 for most of the period, dipped to 0.49 in March 2026, and then rose sharply to 0.69 in the final observation.
- Debt-to-Assets and Financial Leverage
- Debt-to-assets ratios fluctuated within a narrow band of 0.39 to 0.45 until June 30, 2026, where a jump to 0.53 indicates a higher proportion of assets are now financed through debt. Financial leverage followed a general downward trajectory, decreasing from 3.17 in March 2022 to 2.39 in March 2026, reflecting a reduction in the reliance on borrowed funds to amplify returns. This trend was violently interrupted in June 2026, when financial leverage surged to 4.17.
- Interest Coverage Ratio
- Interest coverage showed significant volatility. While the ratio was strong in 2022 and 2023, it experienced a severe contraction in 2024, bottoming out at 1.18 in September 2024, which suggests a temporary period of constrained liquidity or increased interest expense. A strong recovery followed, with the ratio peaking at 11.68 in March 2026. This positive trajectory collapsed in June 2026, as the ratio turned negative to -0.96, indicating that operating earnings were insufficient to cover interest obligations.
The convergence of these metrics in the final quarter indicates a critical shift in the solvency position. The simultaneous spike in all debt-related ratios and the transition of the interest coverage ratio into negative territory suggest a substantial increase in liabilities and a corresponding decline in the ability to service that debt.
Debt Ratios
Coverage Ratios
Debt to Equity
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current portion of long-term debt, net | ||||||||||||||||||||||||
| Long-term debt, net, excluding current portion | ||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||
| Total Gilead stockholders’ equity | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Debt to equity1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Debt to equity = Total debt ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile from March 2022 through June 2026 is characterized by a period of relative stability followed by significant volatility in the capital structure. The debt-to-equity ratio fluctuated between a minimum of 0.94 and a maximum of 2.22, indicating substantial shifts in financial leverage over the observed quarters.
- Total Debt Trends
- Total debt remained relatively stable, generally oscillating between $24.9 billion and $26.2 billion. A temporary reduction was observed in mid-2024, with debt reaching a low of $23.2 billion in September 2024 before spiking to $26.7 billion in December 2024. A similar pattern occurred in early 2026, where debt dropped to $22.1 billion in March before rising again to $26.2 billion by June 2026.
- Stockholders' Equity Fluctuations
- Equity exhibited more pronounced volatility than debt. A steady increase was observed from March 2022 ($19.9 billion) through December 2023 ($22.8 billion). This was followed by a sharp contraction in March 2024, where equity fell to $17.5 billion. Although a recovery trend brought equity to a peak of $23.5 billion by March 2026, a severe decline occurred in June 2026, with equity dropping to $11.8 billion.
- Debt to Equity Ratio Analysis
- The debt-to-equity ratio trended downward from 1.32 in March 2022 to 1.09 in December 2023, reflecting an improvement in solvency. This stability was disrupted in March 2024 when the ratio rose to 1.44, primarily driven by the reduction in equity. The ratio reached its most favorable level of 0.94 in March 2026, the only instance where equity exceeded total debt. However, the period ended with a dramatic increase to 2.22 in June 2026, resulting from the simultaneous increase in total debt and a sharp contraction in stockholders' equity.
Debt to Capital
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current portion of long-term debt, net | ||||||||||||||||||||||||
| Long-term debt, net, excluding current portion | ||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||
| Total Gilead stockholders’ equity | ||||||||||||||||||||||||
| Total capital | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Debt to capital1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the organization exhibits a period of relative stability followed by significant volatility in the final quarters of the observed period. Between March 2022 and December 2024, the debt-to-capital ratio remained largely contained within a range of 0.52 to 0.59, suggesting a consistent approach to capital structure management.
- Total Debt Trends
- Total debt levels fluctuated moderately between $23.2 billion and $26.7 billion throughout most of the analyzed timeframe. A notable peak occurred in December 2024 at $26.7 billion, while the lowest debt level of $22.1 billion was recorded in March 2026. The period concluded with a sharp increase back to $26.2 billion by June 2026.
- Total Capital Fluctuations
- Total capital remained relatively stable, generally ranging between $46 billion and $47 billion from 2022 through 2023. A temporary contraction was observed in the first half of 2024, with capital dipping to $41.6 billion in June 2024 before recovering. A substantial decline occurred toward the end of the sequence, with total capital falling to its lowest point of $38.1 billion by June 2026.
- Debt to Capital Ratio Analysis
- The debt to capital ratio demonstrated a slight downward trajectory from March 2022 (0.57) to December 2023 (0.52). While the ratio fluctuated between 0.54 and 0.59 through 2024 and 2025, a significant shift occurred in 2026. The ratio reached a period low of 0.49 in March 2026, followed by a sharp escalation to a period high of 0.69 in June 2026, indicating a rapid increase in leverage relative to total capital.
Debt to Assets
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current portion of long-term debt, net | ||||||||||||||||||||||||
| Long-term debt, net, excluding current portion | ||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Debt to assets1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the organization exhibits a period of relative stability followed by increased volatility and a rising trend in leverage over the analyzed timeframe. The debt to assets ratio remained consistent during the first two years, but shifted upward as the asset base contracted and debt levels fluctuated, culminating in a significant increase in the final reported quarter.
- Debt to Assets Ratio Trends
- From March 31, 2022, to December 31, 2023, the ratio maintained a narrow range between 0.40 and 0.42, indicating a stable relationship between total obligations and total resources. Starting in March 2024, a shift occurred, with the ratio climbing to a plateau between 0.43 and 0.45 throughout most of 2024 and 2025. While a brief dip to 0.39 was recorded in March 2026, the ratio surged to a period peak of 0.53 by June 30, 2026, representing the highest level of leverage in the dataset.
- Asset Base Contraction
- A primary driver of the increasing solvency ratio is the observed decline in total assets. Assets remained steady around 62 billion US dollars through 2023 but experienced a notable contraction starting in early 2024, dropping to 53.58 billion US dollars by June 2024. Despite some recovery in late 2025, assets fell sharply to 49.36 billion US dollars by June 30, 2026. This reduction in the denominator of the solvency ratio amplified the impact of the company's debt obligations.
- Total Debt Fluctuations
- Total debt demonstrated moderate volatility. After remaining relatively stable near 25 billion US dollars from September 2022 through March 2024, debt levels saw a decrease to 23.25 billion US dollars by September 2024, followed by a sudden spike to 26.71 billion US dollars in December 2024. A similar pattern of volatility appeared in early 2026, where debt dropped to 22.17 billion US dollars in March before rising sharply to 26.25 billion US dollars in June. The simultaneous increase in debt and decrease in assets in the final quarter led to the sharp escalation of the debt to assets ratio.
Financial Leverage
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Total Gilead stockholders’ equity | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Financial leverage1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of financial leverage from March 2022 through June 2026 reveals a period of general deleveraging interrupted by significant volatility in the final quarters. The leverage ratio, reflecting the relationship between total assets and stockholders' equity, shows a long-term trend of reduction until a sharp increase occurs in the final reported period.
- Initial Deleveraging Phase (2022–2023)
- Between March 31, 2022, and December 31, 2023, a consistent downward trend in financial leverage is observed, decreasing from 3.17 to 2.72. This improvement in the solvency profile was driven by stable total assets, which remained within the 62 billion to 63 billion range, and a steady increase in stockholders' equity, which grew from 19.9 billion to 22.8 billion.
- Intermediate Volatility and Recovery (2024–March 2026)
- A temporary spike in leverage to 3.21 occurred in March 2024, coinciding with a contraction in both total assets and stockholders' equity. Following this peak, a sustained period of leverage reduction is evident, with the ratio reaching its lowest point of 2.39 by March 31, 2026. This recovery was supported by a rebound in stockholders' equity, which climbed to a peak of 23.5 billion during this window.
- Final Leverage Escalation (June 2026)
- A significant shift in the financial structure is observed in the final quarter ending June 30, 2026. The financial leverage ratio rose sharply to 4.17, the highest level in the analyzed period. This surge is attributed to a substantial decline in stockholders' equity, which fell from 23.5 billion to 11.8 billion, alongside a reduction in total assets to 49.4 billion. This movement indicates a marked increase in the company's reliance on debt or other liabilities relative to equity.
Interest Coverage
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | ||||||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | ||||||||||||||||||||||||
| Add: Income tax expense | ||||||||||||||||||||||||
| Add: Interest expense | ||||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Interest coverage1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Interest coverage
= (EBITQ2 2026
+ EBITQ1 2026
+ EBITQ4 2025
+ EBITQ3 2025)
÷ (Interest expenseQ2 2026
+ Interest expenseQ1 2026
+ Interest expenseQ4 2025
+ Interest expenseQ3 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The solvency profile of the organization is characterized by extreme volatility in the interest coverage ratio, primarily driven by significant fluctuations in Earnings Before Interest and Taxes (EBIT) rather than changes in debt servicing costs. While interest expenses have remained remarkably stable over the analyzed period, the ability to cover these expenses has varied from high levels of safety to periods of severe operational stress.
- Interest Expense Stability
- Interest expenses demonstrate a consistent pattern, fluctuating within a narrow range between 226 million and 260 million US dollars. This stability indicates a fixed-rate debt structure or a very stable level of outstanding borrowings, meaning the fluctuations in the coverage ratio are entirely attributable to operational performance.
- EBIT Volatility and Operational Impact
- Earnings before interest and tax exhibit severe instability. Following a period of moderate growth in 2022 and 2023, a substantial negative spike occurred on March 31, 2024, with EBIT falling to negative 4,232 million US dollars. Although earnings recovered throughout late 2024 and peaked at 3,897 million US dollars in September 2025, a second and more severe contraction occurred by June 30, 2026, where EBIT dropped to negative 10,007 million US dollars.
- Interest Coverage Ratio Analysis
- The interest coverage ratio mirrors the EBIT volatility. The organization maintained a strong position between 2022 and 2023, with ratios typically ranging from 5.80 to 9.03. A period of solvency risk emerged in 2024, where the ratio declined to a low of 1.18 in September 2024, suggesting that operational earnings were barely sufficient to meet interest obligations. A subsequent recovery saw the ratio climb to a peak of 11.68 by March 31, 2026, before crashing to negative 0.96 in June 2026. The negative ratio at the end of the period indicates that operational losses are currently hindering the organization's ability to service its debt from current earnings.